Is hypofractionation acceptable for prostate bed radiotherapy?
Por:
Campos, FL, Pardo, GS, Pijoan, XM, Zilli, T, Lorenzo, FC, Moron, AH
Publicada:
1 jun 2021
Ahead of Print:
1 jun 2021
Resumen:
Approximately 30% of patients who undergo radical prostatectomy for prostate cancer develop disease progression. The only potentially curative treatment in these patients is postoperative radiotherapy with or without hormonotherapy. One of the standards of care in nonsurgical patients is hypofractionated radiotherapy. However, the current evidence based is insufficient to define the optimal dose and fractionation schedule for postoperative radiotherapy. In this context, the aim of this editorial is to assess the main efficacy and toxicity data for postoperative hypofractionated radiotherapy and discuss the potential to implement this fractionation in routine clinical practice. (C) 2021 Published by Elsevier Inc.
Filiaciones:
Campos, FL:
Hosp Univ Ramon y Cajal, Dept Radiat Oncol, Madrid, Spain
Pardo, GS:
Hosp Santa Creu & Sant Pau, Dept Radiat Oncol, Barcelona, Spain
Pijoan, XM:
Hosp Univ Vall dHebron, Dept Radiat Oncol, Barcelona, Spain
Zilli, T:
Geneva Univ Hosp, Dept Radiat Oncol, Geneva, Switzerland
Lorenzo, FC:
Hosp Univ Quironsalud Madrid, Dept Radiat Oncol, Madrid, Spain
Moron, AH:
Hosp Univ Ramon y Cajal, Dept Radiat Oncol, Madrid, Spain
|